Literature DB >> 17145613

Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome.

Jasper H Smalberg, Sarwa Darwish Murad, Eric Braakman, Peter J Valk, Harry L A Janssen, Frank W G Leebeek.   

Abstract

We studied the etiology, diagnosis and natural course of myeloproliferative disease (MPD) in 40 consecutive patients with Budd-Chiari syndrome (BCS). In 38% of the BCS patients with MPD another etiological factor was found. JAK2 mutation was present in 41% of the tested BCS patients. Survival was not significantly affected by the presence of MPD.

Entities:  

Mesh：

Year:  2006        PMID： 17145613

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  11 in total

Review 1.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

2.  Etiology and portal vein thrombosis in Budd-Chiari syndrome.

Authors:  Oguz Uskudar; Meral Akdogan; Nurgul Sasmaz; Sevinc Yilmaz; Muharrem Tola; Burhan Sahin
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

3.  Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis.

Authors:  Elisabeth P C Plompen; Peter J M Valk; Isabel Chu; Sarwa Darwish Darwish Murad; Aurelie Plessier; Fanny Turon; Jonel Trebicka; Massimo Primignani; Juan Carlos Garcia-Pagán; Dominique C Valla; Harry L A Janssen; Frank W G Leebeek
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

4.  Redefining Budd-Chiari syndrome: A systematic review.

Authors:  Naomi Shin; Young H Kim; Hao Xu; Hai-Bin Shi; Qing-Qiao Zhang; Jean Paul Colon Pons; Ducksoo Kim; Yi Xu; Fei-Yun Wu; Samuel Han; Byung-Boong Lee; Lin-Sun Li
Journal:  World J Hepatol       Date:  2016-06-08

Review 5.  Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.

Authors:  Joan How; Amy Zhou; Stephen T Oh
Journal:  Ther Adv Hematol       Date:  2016-12-08

6.  JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis.

Authors:  Amandeep Salhotra; Thein H Oo
Journal:  Indian J Hematol Blood Transfus       Date:  2012-12-18       Impact factor: 0.900

7.  Thrombophilia: 2009 update.

Authors:  Pat Foy; Stephan Moll
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-04

8.  The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.

Authors:  Ipek Yonal; Binnur Pinarbası; Fehmi Hindilerden; Veysel Sabri Hancer; Meliha Nalcaci; Sabahattin Kaymakoglu; Reyhan Diz-Kucukkaya
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

9.  Splanchnic vein thrombosis, the onset manifestation in JAK positive Chronic Myeloproliferative Disorders Neoplasms.

Authors:  A M Vladareanu; V Popov; H Bumbea; M Onisai; A Ilea; C Dobrea; M Miulescu
Journal:  J Med Life       Date:  2011-02-25

10.  Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg.

Authors:  Mandy N Lauw; Erik W N Bus; Alexander F Y van Wulfften Palthe; Michiel Coppens; Christa H Homburg; Saskia Middeldorp; C Ellen van der Schoot; Harry R Koene; Bart J Biemond
Journal:  Ann Hematol       Date:  2011-04-12       Impact factor: 3.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.